Brief: Summit Therapeutics Collaborates With Pfizer To Evaluate Ivonescimab Trial
24/02/2025 11:44
Feb 24 (Reuters) - Summit Therapeutics Inc SMMT.O :
* SUMMIT THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION
WITH
PFIZER TO EVALUATE IVONESCIMAB IN COMBINATION WITH PFIZER
ANTIBODY DRUG CONJUGATES (ADCS)
* SUMMIT THERAPEUTICS - UNDER TERMS OF AGREEMENT, CO TO
PROVIDE
IVONESCIMAB, PFIZER TO CONDUCT STUDY OPERATIONS
* SUMMIT THERAPEUTICS INC - CLINICAL TRIALS EXPECTED TO
START
MID-YEAR
Source text: ID:nBw9j279fa
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering